Ascendis Pharma A/SASNDNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank69
3Y CAGR+1.8%
5Y CAGR-7.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+1.8%/yr
vs +25.1%/yr prior
5Y CAGR
-7.9%/yr
Recent acceleration
Acceleration
-23.3pp
Decelerating
Percentile
P69
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 12.11% |
| Q3 2025 | -7.10% |
| Q2 2025 | -16.88% |
| Q1 2025 | 9.21% |
| Q4 2024 | 7.82% |
| Q3 2024 | -11.90% |
| Q2 2024 | 18.10% |
| Q1 2024 | -22.22% |
| Q4 2023 | -18.45% |
| Q3 2023 | 6.11% |
| Q2 2023 | -1.03% |
| Q1 2023 | -2.31% |
| Q4 2022 | 11.48% |
| Q3 2022 | 7.80% |
| Q2 2022 | 8.64% |
| Q1 2022 | 26.72% |
| Q4 2021 | 11.73% |
| Q3 2021 | -29.46% |
| Q2 2021 | -5.49% |
| Q1 2021 | 16.37% |
| Q4 2020 | 18.25% |
| Q3 2020 | 0.76% |
| Q2 2020 | 10.54% |
| Q1 2020 | 14.39% |
| Q4 2019 | 8.69% |
| Q3 2019 | 5.55% |
| Q2 2019 | -14.50% |
| Q1 2019 | 34.91% |
| Q4 2018 | 20.58% |
| Q3 2018 | -21.68% |
| Q2 2018 | 31.75% |
| Q1 2018 | 8.94% |
| Q4 2017 | -3.55% |
| Q3 2017 | 32.85% |
| Q2 2017 | 6.17% |
| Q1 2017 | 3.09% |
| Q4 2016 | 21.08% |
| Q3 2016 | 24.33% |
| Q2 2016 | -18.24% |
| Q1 2016 | 29.78% |